# Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation

> **NCT02428296** · PHASE2 · COMPLETED · sponsor: **National Human Genome Research Institute (NHGRI)** · enrollment: 39 (actual)

## Conditions studied

- PIK3CA-Related Overgrowth Spectrum (PROS)
- Growth Disorder
- Genetics

## Interventions

- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT02428296
- **Lead sponsor:** National Human Genome Research Institute (NHGRI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-23
- **Primary completion:** 2018-02-14
- **Final completion:** 2018-02-14
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2020-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02428296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02428296, "Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02428296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*